Novo Nordisk’s MASH Data Strengthens Semaglutide’s Case as Buyback and Earnings Add Context
Novo Nordisk presents Phase 3 ESSENCE subgroup data for semaglutide in MASH, showing efficacy across underrepresented groups. Revenue…
Browsing Tag